255 related articles for article (PubMed ID: 17695436)
21. [Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
Zhang XD; Shen L; Li J; Li Y; Li J; Zhang XT; Jin ML
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):474-7. PubMed ID: 17974288
[TBL] [Abstract][Full Text] [Related]
22. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
[TBL] [Abstract][Full Text] [Related]
23. Is there any place for cytotoxic chemotherapy in endometrial cancer?
Steer C; Harper P
Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):447-67. PubMed ID: 11476565
[TBL] [Abstract][Full Text] [Related]
24. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
Gallagher DJ; Milowsky MI; Bajorin DF
Cancer; 2008 Sep; 113(6):1284-93. PubMed ID: 18629841
[TBL] [Abstract][Full Text] [Related]
25. Systemic treatment for oesophageal cancer.
van Meerten E; van der Gaast A
Eur J Cancer; 2005 Mar; 41(5):664-72. PubMed ID: 15763640
[TBL] [Abstract][Full Text] [Related]
26. Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study.
Hsu FM; Lin CC; Lee JM; Chang YL; Hsu CH; Tsai YC; Lee YC; Cheng JC
J Surg Oncol; 2008 Jul; 98(1):34-41. PubMed ID: 18449912
[TBL] [Abstract][Full Text] [Related]
27. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
28. Innovative drugs and strategies in the treatment of upper gastrointestinal tract carcinomas.
Menges M; Hoehler T
Onkologie; 2004 Feb; 27(1):47-53. PubMed ID: 15007248
[TBL] [Abstract][Full Text] [Related]
29. Palliative therapy.
Homs MY; Kuipers EJ; Siersema PD
J Surg Oncol; 2005 Dec; 92(3):246-56. PubMed ID: 16299791
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy for recurrent cervical carcinoma.
Moore DH
Curr Opin Oncol; 2006 Sep; 18(5):516-9. PubMed ID: 16894302
[TBL] [Abstract][Full Text] [Related]
31. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
Wolff K; Wein A; Reulbach U; Männlein G; Brückl V; Meier C; Ostermeier N; Schwab SA; Horbach T; Hohenberger W; Hahn EG; Boxberger F
Anticancer Drugs; 2009 Mar; 20(3):165-73. PubMed ID: 19125117
[TBL] [Abstract][Full Text] [Related]
32. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemotherapy (FAP) for advanced esophageal cancer.
Shimakawa T; Naritaka Y; Asaka S; Isohata N; Murayama M; Konno S; Yoshimatsu K; Shiozawa S; Katsube T; Ogawa K
Anticancer Res; 2008; 28(4C):2321-6. PubMed ID: 18751413
[TBL] [Abstract][Full Text] [Related]
34. Chemoradiation in the management of esophageal cancer.
Kleinberg L; Forastiere AA
J Clin Oncol; 2007 Sep; 25(26):4110-7. PubMed ID: 17827461
[TBL] [Abstract][Full Text] [Related]
35. Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancer.
Kollmannsberger C; Bokemeyer C
Curr Opin Support Palliat Care; 2008 Sep; 2(3):167-72. PubMed ID: 18685416
[TBL] [Abstract][Full Text] [Related]
36. The combination of 5-fluorouracil, leukovorin, etoposide, and cisplatin (FLEP) in patients with metastatic esophageal cancer. A single-institution experience.
Jonak C; Raderer M; Zacherl J; Prager G; Troch M; Ba-Ssalamah A; Hejna M
Anticancer Res; 2008; 28(6B):4101-4. PubMed ID: 19192667
[TBL] [Abstract][Full Text] [Related]
37. Intermittent therapy in the palliative treatment of metastatic colorectal cancer.
Wadhawan A; Stephens R; Adams R
Expert Rev Anticancer Ther; 2009 Jan; 9(1):125-34. PubMed ID: 19105712
[TBL] [Abstract][Full Text] [Related]
38. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.
Miyoshi N; Yano M; Takachi K; Kishi K; Noura S; Eguchi H; Yamada T; Miyashiro I; Ohue M; Ohigashi H; Sasaki Y; Ishikawa O; Doki Y; Imaoka S
J Surg Oncol; 2009 Apr; 99(5):302-6. PubMed ID: 19170110
[TBL] [Abstract][Full Text] [Related]
39. [A patient with esophageal cancer recurrence responding to S-1 combined with cisplatin (CDDP)].
Kanamori N; Fujii M; Takahashi T; Wakabayashi K; Kochi M; Sou K; Takayama T
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1459-61. PubMed ID: 17876146
[TBL] [Abstract][Full Text] [Related]
40. [Medical treatment of metastatic or recurrent cancer of the cervix].
de la Motte Rouge T; Pautier P; Hamy AS; Duvillard P; Bruna A; Castaigne D; Morice P; Haie-Meder C; Lhommé C
Bull Cancer; 2006 Mar; 93(3):263-70. PubMed ID: 16567313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
